We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Sharmilee
Gnanapavan
s.gnanapavan@qmul.ac.uk
Dr
Sharmilee
Gnanapavan
sharmilee.gnanapavan@nhs.net
Demyelinating diseases of the central nervous system
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
To test the relative occurrence of Anti-drug antibody levels (ADAs) in alemtuzumab treated patients over a two-year period in order to assess their health economic impact infusion-related reactions and disease activity.
In a two year-prospective longitudinal study over the course of treatment with alemtuzumab for RRMS, the long-term clinical implications of anti-alemtuzumab antibody testing will be evaluated. This will be based on clinical and MRI markers of disease activity. This will be used to evaluate the health economic impacts of ADAs.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Interventional type: Active Monitoring;
You can take part if:
You may not be able to take part if:
1. Ineligible for alemtuzumab under NHS England prescribing guidelines. 2. Those unable to comply with study requirements, including frequency of visits. 3. Abnormal baseline investigations (WBC<3 x 10*9/l, lymphocytes <1.0 x 10*9/l, neutrophil count <1.5 x 10*9/l, platelet count <100 x 10*9/l, haemoglobin <110 g/l, LFT >/3x upper limit of normal of site reference ranges, potassium <2.8 mmol/l or >5.5 mmol/l, sodium /,125 mmol/l, creatinine >130 umol/l).
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by BARTS HEALTH NHS TRUST and funded by NIHR Central Commissioning Facility (CCF) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53528
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
